Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 1, 2003, Pages 117-124

  Bolling Sternevald, E ^a,d   Lauritsen, K ^b   Talley, N J ^c   Junghard, O ^d   Glise, H ^a  

^a Dept of Biomedicine and Surgery ^*  (Sweden)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c NEPEAN HOSPITAL   (Australia)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGE; ARTICLE; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WELLBEING;

ADULT; AGED; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; HEALTH STATUS; HEARTBURN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME;

EID: 0041346513     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01651.x     Document Type: Article

References (23)

1. Talley NJ, Colin-Jones D, Koch KL, Koch M, Nyrén O, Stanghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145-60.
2. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJd III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68.
3. Agréus L, Svärdsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 2001; 96: 2905-14.
4. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80.
5. Kagevi I, Löfstedt S, Persson L-G. Endoscopic findings and diagnoses in unselected dyspeptic patients at a primary health care center. Scand J Gastroenterol 1989; 24: 145-50.
6. Talley NJ, Phillips SF. Non ulcer dyspepsia. Potential causes and pathophysiology. Ann Intern Med 1988; 108: 865-79.
7. Talley NJ. Functional dyspepsia - should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther 1995; 9: 107-15.
8. Talley NJ. Drug treatment of functional dyspepsia. Scand J Gastroenterol 1991; 182: 47-60.
9. Fisher RS, Parkman HP. Management of nonulcer dyspepsia. N Engl J Med 1998; 339: 1376-81.
10. Bytzer P, Talley NJ. Current indications for acid suppressants in dyspepsia. Best Pract Res Clin Gastroenterol 2001; 15: 385-400.
11. Wong WM, Wong BCY, Hung WK, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 502-6.
12. Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055-65.
13. Bolling-Stemevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002; 37: 1395-402.
14. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003; 1.
15. Hallerbäck B, Unge P, Carling L. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994; 107: 1305-11.
16. Junghard O, Lauritsen K, Talley NJ, Wiklund I. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia. Eur J Surg Suppl 1998; 583: 106-11.
17. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-52.
18. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. Scand J Gastroenterol 1993; 28: 681-7.
19. Domininguez-Munoz JE, Leodolter A, Sauerbruch T, Malfertheiner P. A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 1997; 40: 459-62.
20. Veldhuyzen van Zanten SJO, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91: 660-73.
21. Blum AL, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 2000; 47: 473-80.
22. Talley NJ, Axon A, Bytzer P, Holtmann G, Lam SK, Veldhuyzen van Zanten SV. Management of uninvestigated and functional dyspepsia: a Working Party Report for the World Congresses of Gastroenterology 1998 [Review]. Aliment Pharmacol Ther 1999; 13(9): 1135-48.
23. Talley NJ, Silverstein MD, Agréus L, Nyrén O, Sonnenberg A, Holtmann G. AGA Technical Review: evaluation of dyspepsia. Gastroenterology 1998; 114: 582-95.